The Primary objective of this study is to determine, using unblinded samples, if it ispossible to develop an algorithm for the classification of specific blood RNA frompatients with long COVID together and separately from the apparent health normal controlsand other medical conditions that share the signs and symptoms of long COVID.
Participants will be screened and provide two blood samples28 (+/- 2) days apart. Based
on the participants survey results they will be placed into one of fourteen groups that
reflect the type of Long COVID the patient is experiencing. Samples will be shipped to
the sponsor who will develop an AI process to validate the type of Long COVID and assess
its severity. The long term goal is to develop a reliable test to identify the presence
of Long COVID and its severity.
Diagnostic Test: RNA Biomarker Blood Test
Blood will be collected into a PaxGene Blood tube for processing by sponsor
Inclusion Criteria:
- Mentally capable of understanding and completing informed consent for the study.
- Precipitants with a lab verified diagnosis of SARS-CoV-2 or clinician note/record
that an appropriate rapid test for SARS-CoV-2 was positive.
- To qualify for long COVID group participants will need to have new, persistent
symptoms related to SARS-CoV-2 infection. iv. No one under the age of 18.
Exclusion Criteria:
- Subject is unable to provide informed consent.
- Primary Investigator or Sub-Investigator determines the participant's ongoing
medical complaints that began after 1 November 2019 are not related to SARS-COV-2
but another disease process.
University of Iowa
Iowa City, Iowa, United States
The MaxWell Clinic
Brentwood, Tennessee, United States
The MaxWell Clinic
Brentwood, Tennessee, United States
Not Provided